TMCnet News

Arca biopharma Names Robert Conway as Chairman of Board [Health & Beauty Close - Up]
[June 12, 2014]

Arca biopharma Names Robert Conway as Chairman of Board [Health & Beauty Close - Up]


(Health & Beauty Close - Up Via Acquire Media NewsEdge) Arca biopharma said that Robert E. Conway has been elected Chairman of the Company's Board of Directors.

Arca said he serves on the Audit and Compensation Committees of the Board of Directors.

According to a company release, Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries.

Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012.

Prior to joining Array, Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, a clinical research services company, from 1996 to 1999.

He also held various executive positions for Corning, including Corporate Vice President and General Manager of Corning Hazleton, a contract research organization. Conway serves as the Chairman of Wall Family Enterprise, a library and education supplies company.



He is on the Board of Directors of eResearch Technology. In addition, Conway is a member of the Strategic Advisory Committee of Genstar Capital.

"Bob's experience and leadership are a tremendous asset to Arca," said Dr. Michael R. Bristow, President and Chief Executive Officer of Arca. "With his significant experience in leading both drug development efforts and companies in the biopharmaceutical sector, Bob's input and guidance be valuable to the Arca Board as we continue the development of Gencaro and look to deliver value to our stockholders." "I am honored to accept this role with the Arca Board of Directors," said Conway. "This is an exciting time for the organization with the GENETIC-AF trial under way. We believe there is an unmet medical need for new atrial fibrillation treatments. The GENETIC-AF trial, conducted with the collaboration of Medtronic, will hopefully provide important new data for the atrial fibrillation community." Arca biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases.


Array is a biopharmaceutical company.

More information and complete details: www.arcabiopharma.com ((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved.

[ Back To TMCnet.com's Homepage ]